Form 4: AnaptysBio CLO Exercises Options, Sells Shares
Insider Transaction Report
AnaptysBio's Chief Legal Officer, Eric J. Loumeau, exercised stock options and subsequently sold 10,000 shares of common stock for $51 per share, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc., engaged in a transaction on December 22, 2025.
- Loumeau exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $14.02 per share.
- Concurrently, Loumeau sold 10,000 shares of common stock at a price of $51 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on April 11, 2025.
- Following these transactions, Loumeau directly owns 8,947 shares of common stock.
- Loumeau also holds options to purchase an aggregate of 457,810 shares of common stock, including 43,000 fully vested options and 414,810 options vesting according to their terms.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive due to the insider realizing a significant profit from their equity compensation, and the transaction being pre-planned under a 10b5-1 plan, which reduces concerns about opportunistic selling. However, it's a routine disclosure and does not reflect company operational performance.
Positives
- The insider realized a significant profit by exercising options at $14.02 and selling shares at $51, indicating a positive personal financial outcome from their equity compensation.
- The sale was conducted under a pre-arranged 10b5-1 trading plan, which suggests the transaction was not based on new, non-public information and is a routine part of an executive's compensation management.
Negatives
- An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence, though this is often mitigated by the pre-planned nature and the fact that it is a common way for executives to diversify holdings and manage liquidity.
Future Outlook
Not applicable, as this filing reports a past insider transaction and does not contain forward-looking statements or guidance.
Industry Context
This Form 4 filing is a routine disclosure of an insider's equity transaction and does not provide information relevant to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reporting person adopted a Rule 10b5-1 trading plan on April 11, 2025, under which the reported transactions were effected. This plan allows insiders to sell shares at a pre-determined time or price to avoid accusations of insider trading. | 2025-04-11 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reporting person's transactions. |
Stakeholder Impact
- Shareholders: Provides transparency regarding insider stock transactions, which can influence investor sentiment, though the 10b5-1 plan mitigates concerns.
- Employees: Demonstrates how executive equity compensation is monetized, which can be relevant for employee stock option holders.
Key Dates
| Date | Description |
|---|---|
| 2025-04-11 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 2025-12-22 | Date of the stock option exercise and subsequent sale of common stock. |
| 2025-12-23 | Date the Form 4 was signed by Eric Loumeau. |
| 2029-12-05 | Expiration date of the employee stock option that was exercised. |
Keywords
ANAPTYSBIO, ANAB, Form 4, insider trading, stock option exercise, share sale, 10b5-1 plan, Chief Legal Officer, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.